Format

Send to:

Choose Destination
See comment in PubMed Commons below
Emerg Infect Dis. 2011 Oct;17(10):1807-15. doi: 10.3201/eid1710.110117.

Oseltamivir-resistant pandemic (H1N1) 2009 virus infection in England and Scotland, 2009-2010.

Author information

  • 1Health Protection Agency, London, UK. calatayudlaurence@yahoo.com

Abstract

Oseltamivir has been widely used for pandemic (H1N1) 2009 virus infection, and by April 30, 2010, a total of 285 resistant cases were reported worldwide, including 45 in the United Kingdom. To determine risk factors for emergence of oseltamivir resistance and severe infection, a case-control study was conducted in the United Kingdom. Study participants were hospitalized in England or Scotland during January 4, 2009-April 30, 2010. Controls had confirmed oseltamivir-sensitive pandemic (H1N1) 2009 virus infections, and case-patients had confirmed oseltamivir-resistant infections. Of 28 case-patients with available information, 21 (75%) were immunocompromised; 31 of 33 case-patients (94%) received antiviral drugs before a sample was obtained. After adjusting for confounders, case-patients remained significantly more likely than controls to be immunocompromised and at higher risk for showing development of respiratory complications. Selective drug pressure likely explains the development of oseltamivir resistance, especially among immunocompromised patients. Monitoring of antiviral resistance is strongly recommended in this group.

PMID:
22000349
[PubMed - indexed for MEDLINE]
PMCID:
PMC3310668
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for CDC-NCEZID Icon for PubMed Central
    Loading ...
    Write to the Help Desk